This message is sent to all Alzheimer’s Association and Alzheimer’s Impact Movement board members, all Alzheimer’s Association staff, and volunteers and supporters of AIM and the Alzheimer’s Association.

We have an exciting major development about the potential for a new treatment for Alzheimer’s disease, and we wanted to share the positive results with you as quickly as possible.

Tonight, initial clinical trial results were announced for a drug called lecanamab which was tested in individuals living with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s dementia. Results from the clinical trial found that this treatment significantly reduces clinical decline from the disease.

These are the most encouraging results in clinical trials treating the underlying causes of Alzheimer’s to date. These results indicate lecanamab may give people more time at or near their full abilities to participate in daily life, remain independent and make future health care decisions.

We will know more at the end of November when the data behind these initial results will be public. We look forward to learning more at that time about participant safety and representation in the trials. It’s also important to manage our own expectations that this treatment is not yet Food and Drug Administration (FDA) approved and is not yet available in doctors’ offices.

This is a major milestone for Alzheimer’s disease treatments. It is a significant gain for people with the disease and their families and it further positions us to advance our mission in new and exciting ways.

We have never been more hopeful, and we hope you share our excitement. Even with the success announced today, we must redouble efforts to discover new targets and test new and more effective treatments for Alzheimer’s and all other dementia.

Thank you for all that you have done, all you are doing, and all you will do to make this a reality.